Kiniksa Pharmaceuticals Q1 2025 Update
Ticker: KNSA · Form: 10-Q · Filed: 2025-04-29T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Kiniksa Q1 2025: Assets $1.61B, Liabilities $41.88M, Equity $1.57B. Solid financials.
AI Summary
Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial figures include total assets of $1.61 billion and total liabilities of $41.88 million as of March 31, 2025. The company reported total equity of $1.57 billion.
Why It Matters
This filing provides investors with a quarterly snapshot of Kiniksa Pharmaceuticals' financial health and operational standing, crucial for investment decisions.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative events indicated.
Key Numbers
- $1.61B — Total Assets (As of March 31, 2025)
- $41.88M — Total Liabilities (As of March 31, 2025)
- $1.57B — Total Equity (As of March 31, 2025)
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Filer
- 20250331 (date) — Reporting period end date
- 20250429 (date) — Filing date
- $1.61 billion (dollar_amount) — Total assets as of March 31, 2025
- $41.88 million (dollar_amount) — Total liabilities as of March 31, 2025
- $1.57 billion (dollar_amount) — Total equity as of March 31, 2025
FAQ
What were Kiniksa's total assets as of March 31, 2025?
Kiniksa's total assets were $1,605,761,800 as of March 31, 2025.
What were Kiniksa's total liabilities as of March 31, 2025?
Kiniksa's total liabilities were $41,881,319 as of March 31, 2025.
What was Kiniksa's total equity as of March 31, 2025?
Kiniksa's total equity was $1,563,880,481 as of March 31, 2025.
What is Kiniksa Pharmaceuticals International, plc's SIC code?
The Standard Industrial Classification code for Kiniksa Pharmaceuticals International, plc is 2834, Pharmaceutical Preparations.
When was Kiniksa Pharmaceuticals, Ltd. renamed to Kiniksa Pharmaceuticals International, plc?
The company's name changed from Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals International, plc on February 5, 2018.
From the Filing
0001558370-25-005847.txt : 20250429 0001558370-25-005847.hdr.sgml : 20250429 20250429161530 ACCESSION NUMBER: 0001558370-25-005847 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25887799 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 10-Q 1 knsa-20250331x10q.htm 10-Q Kiniksa Pharmaceuticals International, plc_March 31, 2025 0 0 0 0 0 0 16057618 16057618 00-0000000 41881319 42162592 1795158 1795158 1795158 12781964 12781964 12781964 0001730430 --12-31 2025 Q1 false 0001730430 us-gaap:RetainedEarningsMember 2025-03-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001730430 us-gaap:RetainedEarningsMember 2024-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001730430 us-gaap:RetainedEarningsMember 2024-03-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001730430 us-gaap:RetainedEarningsMember 2023-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730430 knsa:EquityIncentivePlan2015Member us-gaap:CommonClassAMember 2025-03-31 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:CommonClassAMember 2024-12-31 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:CommonClassAMember 2025-01-01 2025-03-31 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:CommonClassAMember 2025-03-31 0001730430 knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2025-03-31 0001730430 knsa:IncentiveAwardPlan2018Member 2025-03-31 0001730430 srt:MaximumMember knsa:IncentiveAwardPlan2018Member us-gaap:CommonClassAMember 2025-01-01 2025-01-01 0001730430 srt:MaximumMember knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2025-01-01 2025-01-01 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001730430 us-gaap:PerformanceSharesMember 2024-12-31 0001730430 knsa:RestrictedStockUnitsRsuTimeBasedMember 2025-01-01 2025-03-31 0001730430 us-gaap:ProductMember knsa:PharmaceuticalSegmentMember 2025-01-01 2025-03-31 0001730430 us-gaap:ProductMember knsa:PharmaceuticalSegmentMember 2024-01-01 2024-03-31 0001730430 knsa:CollaborationMember knsa:PharmaceuticalSegmentMember 2024-01-01 2024-03-31 0001730430 knsa:CollaborationMember knsa:WorldwideLicenseVixarelimabMember 2025-01-01 2025-03-31 0001730430 knsa:CollaborationMember knsa:TerritoryLicenseArcalystMember 2025-01-01 2025-03-31 0001730430 us-gaap:ProductMember 2025-01-01 2025-03-31 0001730430 knsa:CollaborationMember knsa:WorldwideLicenseVixarelimabMember 2024-01-01 2024-03-31 0001730430 knsa:CollaborationMember knsa:TerritoryLicenseArcalystMember 2024-01-01 2024-03-31 0001730430 us-gaap:ProductMember 2024-01-01 2024-03-31 0001730430 knsa:CollaborationMember 2024-01-01 2024-03-31 0001730430 knsa:CollaborationMember knsa:TerritoryLicenseMavrilimumabMember 2022-01-01 2022-12-31 0001730430 knsa:UnallocatedResearchAndDevelopmentMember knsa:PharmaceuticalSegmentMember 2025-01-01 2025-03-31 0001730430 knsa:RegeneronPharmaceuticalsIncMember knsa:ClinicalSupplyAgreementMember 2025-01-01 2025-03-31 000173